-+ 0.00%
-+ 0.00%
-+ 0.00%

Cochlear (ASX:COH), What Is Behind The Fresh Attention?

Simply Wall St·11/17/2026 17:09:57
Listen to the news

Cochlear event recap and why it matters now

Cochlear (ASX:COH) has paired fresh 2027 earnings guidance, flagging modest revenue growth, with news that North America President Lisa Aubert will depart after more than three decades at the business.

Investors have seen mixed signals around Cochlear recently, with the 1 month share price return of 15.02% and 90 day gain of 6.82% sitting against a year to date share price decline of 42.21% and a 1 year total shareholder return that has fallen 43.49%. This suggests the new 2027 guidance and leadership change are being weighed against a longer stretch of weaker performance.

Compare Cochlear's recent swings with other healthcare peers by scanning our hand picked 5 resilient stocks with low risk scores that have shown more resilient return profiles.

Cochlear shares have bounced hard in the last month while the stock still trades above the average analyst target and below some intrinsic value estimates. Where does fair value really sit in that spread?

Most Popular Narrative: 11% Overvalued

Cochlear last closed at A$150.83, while the analyst consensus Narrative on Simply Wall St anchors fair value at A$136.34 and applies a 7.48% discount rate to its cash flows and earnings path.

The main thing that has to go right is Cochlear turning its adult medicalization programs, new implant platforms and cost restructuring into higher quality referrals, a better product mix and a recovery in margins toward its stated targets.

The current valuation of Cochlear implies the share price already reflects a recovery from recent earnings pressure and that the company is fairly valued based on expectations of moderate revenue growth, steady R&D investment and gradual margin repair.

See why 52 investors see Cochlear as 11% overvalued.

Result: Fair Value of A$136.34 (OVERVALUED)

Still, the Cochlear story depends on referral programs and margin repair not stalling, while pricing pressure in China and other emerging markets could continue to weigh on profitability.

Find out about the key risks to this Cochlear narrative.

Another View: SWS DCF Points To Upside

The analyst consensus on Cochlear leans toward A$136.34 as fair value, yet the SWS DCF model comes out very differently. On that approach, the shares trade around A$150.83 against an estimated future cash flow value of A$225.25, which screens as undervalued. Which signal should carry more weight for you?

Look into how the SWS DCF model arrives at its fair value.

COH Discounted Cash Flow as at Nov 2026
COH Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cochlear for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 2 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed feelings about Cochlear's outlook are clear, so move fast on the numbers, stress test the assumptions for yourself and then check the 2 key rewards and 2 important warning signs.

Looking for more Cochlear sized investment ideas?

If Cochlear has you rethinking your watchlist, use the Simply Wall St screener to quickly spot fresh opportunities that match your style before others move first.